Patents by Inventor Malte Meppen

Malte Meppen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS TO MEASURE THE CONCENTRATION OF ALUMINIUM HYDROXIDE IN MENB VACCINES
    Publication number: 20250244344
    Abstract: The present invention relates inter alia to methods of measuring the concentration of aluminium hydroxide in MenB vaccines.
    Type: Application
    Filed: October 20, 2022
    Publication date: July 31, 2025
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Lorenzo DI MEOLA, Agnese MARCELLI, Malte MEPPEN, Daniela PASQUI, Daniela STRANGES
  • Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection
    Patent number: 8148349
    Abstract: The present invention provides nucleoside cyclic phosphoramidates of formula (I), pharmaceutical compositions comprising the compounds of formula (I) and methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection using the compounds of formula (I).
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: April 3, 2012
    Assignees: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.P.A., Merck Sharp & Dohme Corp.
    Inventors: Malte Meppen, Frank Narjes, Barbara Pacini, Cristina Gardelli, Philippe L. Durette
  • Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
    Patent number: 7879815
    Abstract: The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside aryl phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramidates of the present invention.
    Type: Grant
    Filed: February 12, 2007
    Date of Patent: February 1, 2011
    Assignees: Merck Sharp & Dohme Corp., Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Malcolm MacCoss, David B. Olsen, Monica Donghi, Cristina Gardelli, Steven Harper, Malte Meppen, Frank Narjes, Barbara Pacini
  • Nucleoside Aryl Phosphoramidates for the Treatment of RNA-Dependent RNA Viral Infection
    Publication number: 20100234316
    Abstract: The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside aryl phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramidates of the present invention.
    Type: Application
    Filed: February 12, 2007
    Publication date: September 16, 2010
    Inventors: Malcolm MacCoss, David B. Olsen, Monica Donghi, Cristina Gardelli, Steven Harper, Malte Meppen, Frank Narjes, Barbara Pacini
  • Antiviral Agents
    Publication number: 20100152128
    Abstract: A compound of formula (I) and pharmaceutically acceptable salts thereof; compositions containing it and its use in medicine, particularly for the treatment or inhibition of HCV infections, and processes for making it are disclosed.
    Type: Application
    Filed: May 19, 2008
    Publication date: June 17, 2010
    Inventors: Barbara Attenni, Monica Donghi, Cristina Gardelli, Malte Meppen, Frank Narjes, Barbara Pacini
  • NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION
    Publication number: 20100022468
    Abstract: The present invention provides nucleoside cyclic phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as pre-cursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside cyclic phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside cyclic phosphoramidates of the present invention.
    Type: Application
    Filed: December 14, 2007
    Publication date: January 28, 2010
    Inventors: Malte Meppen, Frank Narjes, Barbara Pacini, Cristina Gardelli, Philippe L. Durette